Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Aims

The key aim of the GHSG is to optimize and standardize diagnostics, therapy and follow-up care in Hodgkin lymphoma patients. This is to be achieved by the following scientific and structural measures:

Scientific measures

  • Conducting prospective, randomized, stage-adapted multicenter trials,
  • Minimizing treatment-related adverse reactions while maintaining treatment efficacy,
  • Individualizing therapy,
  • Documenting adverse effects of treatment such as infertility, late toxicities and secondary malignancies,
  • Examining the patients’ quality of life,
  • Identifying risk factors,
  • Introducing and establishing new agents in Hodgkin lymphoma therapy and
  • Developing new innovative treatment regimens.

Structural measures

  • Involving as many hospitals and oncology practices in the trials as possible, both at national and international level,
  • Having diagnoses confirmed by the review pathologists of the German lymphoma trials,
  • Cooperating with different medical specialists, such as oncologists, radiotherapists, nuclear-medical specialists, pathologists and specialists for fundamental research, statistics and other areas, on a sustained basis,
  • Cooperating with self-help group and supporting these groups.